FTC Blocks Edwards' $1.2B Acquisition of JenaValve Amid Antitrust Concerns

Source: Medical Device Business Review

Recently, according to reports by The Wall Street Journal, Bloomberg, Reuters and other media,Federal Trade Commission (FTC)（FTC）Blocking Edwards Lifesciences on Antitrust Grounds(Edwards, hereinafter referred to as: Edwards)TargetingJenaValve's Acquisition Plan.

JenaValve, headquartered in Munich, has a core product ofTrilogy Heart Valve System，SystemThe world's first and onlyOne Approved（CE）Transfemoral TAVR for the treatment of severe symptomatic aortic regurgitation or aortic stenosis.

Source: JenaValve Trilogy Official Website

The origin of JenaValve can be traced back to the design concept proposed in 1995 by Dr. Hans Figulla and Dr. Markus Ferrari from Friedrich Schiller University. The founders obtained their first patent for a percutaneous self-expanding aortic stent in 1999.

In 2006, JenaValve was officially established. In 2018, the company initiated the ALIGN-AR pivotal trial in the United States, utilizing its transcatheter porcine pericardial valve to treat aortic regurgitation.

In 2021, the company raised $100 million in a Series C financing round aimed at obtaining FDA approval for its Trilogy heart valve system, which is designed for high surgical risk patients with symptomatic severe aortic regurgitation (AR).

In the same year, China's leading cardiovascular enterprisesPeijia MedicalEntered into an exclusive license agreement with JenaValve for the Trilogy™ Heart Valve System in the Greater China region and became one of the minority shareholders of JenaValve. After the completion of this transaction, Peijia Medical will continue to hold the rights to the JenaValve Trilogy THV system in...Exclusive Authorization in Greater China。

In October of the year before last, JenaValve appeared at the Transcatheter Cardiovascular Therapeutics conference.(TCT)Meeting, ALIGN-ARCo-principal investigator Vinod Thourani announced the experimental results,Announced that the study met its primary safety endpoint, which was to evaluate the safety of the Trilogy THV system 30 days after implantation. Regarding efficacy, the researchers indicated significant improvements in left ventricular systolic diameter, systolic volume, and mass regression.

In this acquisition, officials from Edwards Lifesciences mentioned,The JenaValve Trilogy heart valve system for treating aortic regurgitation may receive FDA approval by the end of 2025.

02

As the approval date for JenaValve Trilogy approaches, analysts last month hadUpgraded Edward's Rating。

However, at this critical juncture, the Federal Trade Commission (FTC) The commission suddenly announced a lawsuit to block Edwards Lifesciences from acquiring JenaValve Technology, Inc., according to a lawsuit filed on Wednesday in Washington.Edward and JenaValve are currently the only two companies in the United States conducting clinical trials on transcatheter aortic valve replacement devices.This merger will reduce competition in the market for devices used to treat potentially fatal heart conditions.

Daniel Guanella, Director of the Bureau of Competition of the U.S. Federal Trade Commission(Daniel Guarnera)"In a statement, the U.S. Federal Trade Commission said it is taking action to block this anti-competitive transaction and ensure that JenaValve and Edwards' JC Medical subsidiary continue to compete in innovation, expand treatment eligibility, and reduce costs."

Edward responded: "We disagree with the FTC's decision.,and believes that this will limit the possibility for AR patients to access an important treatment option. The company further believes that the acquisition of JenaValve will accelerate AR patients' access to, adoption of, and ongoing innovation in a life-saving treatment method."

Despite the Federal Trade Commission(FTC)Despite attempts to block the deal, Edward still intends to proceed with seeking regulatory approval,The company expects the final decision to be made by the end of the first quarter of 2026.

In view of this move, the company revised its full-year performance forecast. The company expects that this acquisition will not impact revenue but has raised the upper limit of its adjusted earnings per share (EPS) guidance from $2.40–$2.50 to $2.45–$2.55. The company anticipates that the acquisition will have a negligible effect on the adjusted EPS forecast for the third quarter.

JenaVAlve stated its intentionIn collaboration with EdwardDefense in court to complete the acquisition: "JenaValve respects and opposes the Federal Trade Commission's decision and will continue to be committed to completing the acquisition. JenaValve is confident in the rationale of this transaction and the value it will bring to hundreds of thousands of patients with aortic regurgitation."

Conclusion

At this point, Edward's ambitious acquisition plan has encountered a strong blockade by the FTC in the name of antitrust. On one side is the regulatory agency's determination to maintain market competition and prevent giant monopolies; on the other side is the industry giant's demand to consolidate resources and accelerate the popularization of innovative therapies. Both sides stick to their own arguments and have expressed their intention to resort to the court.

The outcome of this battle for the future landscape of the heart valve market will become clear in early 2026. Hanging in the balance is not only the commercial interests of the two companies but also the critical progress regarding whether patients with global aortic regurgitation can timely access this "world's only" innovative therapy.